Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Galecto, Inc.

$28.69

-0.06 (-0.21%)

D 21Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.73 B
EPS
-12.10
P/E Ratio
-
Value Trade
6.55 M
SEC Financials
Q3 2025

  • Dilution Risk

    95%

  • R&D Expenses

    1.42 M

  • Total Assets

    10.74 M

  • Total Liabilities

    2.73 M

  • Equity

    8.01 M

  • D/E Ratio

    12,345

-1.95 %
Week
24.2 %
1 Month
11.5 %
3 Month
999.23 %
6 Month
-88.23 %
5 Year
-92.35 %
All Time
Cash Data
Critical

  • Cash Position

    7.61 M

  • Monthly Burn

    1.05 M

  • Runway

    2.9 mo

  • Burn Trend

    Stable

  • SEC Filing

    Nov 6, 2025
Overview
Volume
231.69 K
52 Week Range
2.01 - 38.33
% held by Insiders
25.3 %
% held by Institutions
74.12 %
Enterprise Value
1.72 B
Total Shares
1.60 M
Short %
41.59 %
Float Shares
781.57 K
Company Description
Founded:2011

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Clearance example
BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners)
IND
—
Small Molecules
-
BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners)
IND
—
Small Molecules
-
BRM-1420 (also referred to as GB3226) Acute myeloid leukemia (AML) — multiple genetic subsets (monotherapy and combination partners)
IND
—
Small Molecules
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D21
Pipeline Score
$26M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.0x
rNPV / MCap
Top 19%
Micro Cap
(rank 734 of 905)
Percentile Rank
Galecto, Inc. faces pipeline headwinds (21/100), with $308M risk-adjusted pipeline value, led by GB1211 in Metastatic Melanoma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
GB1211
Small molecule		Metastatic MelanomaPhase 2NCT0591338819% $210M RECRUITING 92 - -Feb 1, 2030 -LOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
GB3226
acute myeloid leukemia (AML)
Preclinical
2025-08-06
GB3226
acute myeloid leukemia (AML)
Preclinical
2025-08-06
GB3226
acute myeloid leukemia (AML)
Preclinical
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in GLTO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Galecto, Inc. (GLTO) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
GLTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GLTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
GLTO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
GLTO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How GLTO ranks across every disease it competes in
Competitive Position is a premium feature
See how GLTO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial